1.Phillips, B, Ball, C, Sackett, D, et al.Oxford Centre for Evidence-based Medicine levels of evidence (May 2001). Available: www.cebm.net/levels_of_evidence.asp (accessed March 2008).
2.Strehlow, MC, Emond, SD, Shapiro, NI, et al.National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006;48:326–31, 331.e1–3.
3.Martin, GS, Mannino, DM, Eaton, S, et al.The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 17;348:1546–54.
4.Angus, DC, Linde-Zwirble, WT, Lidicker, J, et al.Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–10.
5.Lambe, S, Washington, DL, Fink, A, et al.Trends in the use and capacity of california’s emergency departments, 1990–1999. Ann Emerg Med 2002;39:389–96.
6.Meggs, WJ, Czaplijski, T, Benson, N. Trends in emergency department utilization, 1988–1997. Acad Emerg Med 1999;6:1030–5.
7.Parkhe, M, Myles, PS, Leach, DS, et al.Outcome of emergency department patients with delayed admission to an intensive care unit. Emerg Med (Fremantle) 2002;14:50–7.
8.Nelson, M, Waldrop, RD, Jones, J, et al.Critical care provided in an urban emergency department. Am J Emerg Med 1998;16:56–9.
9.Varon, J, Fromm, RE Jr, Levine, RL. Emergency department procedures and length of stay for critically ill medical patients. Ann Emerg Med 1994;23:546–9.
10.Svenson, J, Besinger, B, Stapczynski, JS. Critical care of medical and surgical patients in the ED: Length of stay and initiation of intensive care procedures. Am J Emerg Med 1997;15:654–7.
11.Sampalis, JS, Denis, R, Lavoie, A, et al.Trauma care regionalization: a process-outcome evaluation. J Trauma 1999;46:565,79; discussion 579–81.
12.Rivers, E, Nguyen, B, Havstad, S, et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–77.
13.Cannon, CP, Gibson, CM, Lambrew, CT, et al.Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941–7.
14.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–7.
15.Bernard, GR, Vincent, JL, Laterre, PF, et al.Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
16.Annane, D, Sebille, V, Charpentier, C, et al.Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862–71.
17.van den, BG, Wouters, P, Weekers, F, et al.Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–67.
18.Bochud, PY, Bonten, M, Marchetti, O, et al.Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S495–512.
19.Garnacho-Montero, J, Garcia-Garmendia, JL, Barrero-Almodovar, A, et al.Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–51.
20.Leibovici, L, Shraga, I, Drucker, M, et al.The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244 :379–86.
21.Leone, M, Bourgoin, A, Cambon, S, et al.Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003;31:462–7.
22Levy, MM, Fink, MP, Marshall, JC, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–6.
23.Hotchkiss, RS, Karl, IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138–50.
24.Rivers, EP, McIntyre, L, Morro, DC, et al.Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005;173:1054–65.
25.Bone, RC, Balk, RA, Cerra, FB, et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–55.
26.Rivers, E. The outcome of patients presenting to the emergency department with severe sepsis or septic shock. Crit Care 2006;10:154.
27.Hebert, PC, Drummond, AJ, Singer, J, et al.A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993;104:230–5.
28.Nguyen, HB, Rivers, EP, Knoblich, BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637–12.
29.Pinsky, MR. Cardiovascular effects of ventilatory support and withdrawal. Anesth Analg 1994;79:567–76.
30.Sugerman, HJ, Diaco, JF, Pollock, TW, et al.Physiologic management of septicemic shock in man. Surg Forum 1971;22:3–5.
31.Turnaoglu, S, Tugrul, M, Camci, E, et al.Clinical applicability of the substitution of mixed venous oxygen saturation with central venous oxygen saturation. J Cardiothorac Vasc Anesth 2001;15:574–9.
32.Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999;27:639–60.
33.Rackow, EC, Falk, JL, Fein, IA, et al.Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypo-volemic and septic shock. Crit Care Med 1983;11:839–50.
34.Finfer, S, Norton, R, Bellomo, R, et al.The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. Vox Sang 2004;07(Suppl 2):123–31.
35.Bunn, F, Alderson, P, Hawkins, V. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2003;(1):CD001319.
36.Roberts, I, Alderson, P, Bunn, F, et al.Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2004;(4):CD000567
37.Alderson, P, Bunn, F, Lefebvre, C, et al.Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004;(4):CD001208.
38.Upadhyay, M, Singhi, S, Murlidharan, J, et al.Randomized evaluation of fluid resuscitation with crystalloid (saline) and colloid (polymer from degraded gelatin in saline) in pediatric septic shock. Indian Pediatr 2005 ;42:223–31.
39.Vincent, JL, Gerlach, H. Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S451–4.
40.Brunkhorst, FM, Engel, C, Bloos, F, et al.Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–39.
41.Holmes, CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 2005;11:413–7.
42.Holmes, CL, Walley, KR. The evaluation and management of shock. Clin Chest Med 2003;24:775–89.
43.Nguyen, HB, Rivers, EP, Abrahamian, FM, et al.Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe sepsis and septic shock: review of the literature and emergency department man-agement guidelines. Ann Emerg Med 2006;48:28–54.
44.Dellinger, RP, Carlet, JM, Masur, H, et al.Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–73.
45.Kuhl, DA. Current strategies for managing the patient with sepsis. Am J Health Syst Pharm 2002;02/15(Suppl 1):S9–13.
46.Hollenberg, SM, Ahrens, TS, Annane, D, et al.Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928–48.
47.De Backer, D, Creteur, J, Silva, E, et al.Effects of dopamine, nor-epinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003;31:1659–67.
48.Martin, C, Viviand, X, Leone, M, et al.Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758–65.
49.Martin, C, Papazian, L, Perrin, G, et al.Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826–31.
50.Marik, PE, Mohedin, M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354–7.
51.Redl-Wenzl, EM, Armbruster, C, Edelmann, G, et al.The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19:151–4.
52.Levy, B, Bollaert, PE, Charpentier, C, et al.Comparison of nor-epinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997;23:282–7.
53.Desjars, P, Pinaud, M, Potel, G, et al.A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987;15:134–7.
54.Meadows, D, Edwards, JD, Wilkins, RG, et al.Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988;16:663–6.
55.Desjars, P, Pinaud, M, Bugnon, D, et al.Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989;17:426–9.
56.Hesselvik, JF, Brodin, B. Low dose norepinephrine in patients with septic shock and oliguria: effects on afterload, urine flow, and oxygen transport. Crit Care Med 1989;17:179–80.
57.Marin, C, Eon, B, Saux, P, et al.Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18:282–5.
58.Bellomo, R, Chapman, M, Finfer, S, et al.Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139–43.
59.Kellum, JA, Decker, M. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526–31.
60.Olson, D, Pohlman, A, Hall, JB. Administration of low-dose dopamine to nonoliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance. Am J Respir Crit Care Med 1996;154:1664–70.
61.Patel, BM, Chittock, DR, Russell, JA, et al.Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576–82.
62.Malay, MB, Ashton, RC Jr, Landry, DW, et al.Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699–703.
63.Holmes, CL, Walley, KR, Chittock, DR, et al.The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416–21.
64.Dufresne, RG Jr. Skin necrosis from intravenously infused materials. Cutis 1987;39:197–8.
65.Greenwald, RA, Rheingold, OJ, Chiprut, RO, et al.Local gangrene: a complication of peripheral pitressin therapy for bleeding esophageal varices. Gastroenterology 1978;74:744–6.
66.Kahn, JM, Kress, JP, Hall, JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002;30:1899–901.
67.Korenberg, RJ, Landau-Price, D, Penneys, NS. Vasopressin-induced bullous disease and cutaneous necrosis. J Am Acad Dermatol 1986;15:393–8.
68.Rudis, MI, Basha, MA, Zarowitz, BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996;24:525–37.
69.Cohen, J, Brun-Buisson, C, Torres, A, et al.Diagnosis of infection in sepsis: an evidence-based review. Crit Care Med 2004;32:S466–94.
70.Smith-Elekes, S, Weinstein, MP. Blood cultures. Infect Dis Clin North Am 1993;7:221–34.
71.Reimer, LG, Wilson, ML, Weinstein, MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997;10:444–65.
72.Wilson, ML. General principles of specimen collection and transport. Clin Infect Dis 1996;22:766–77.
73.Broder, G, Weil, MH. Excess lactate: an index of reversibility of shock in human patients. Science 1964;143:1457–9.
74.Bernardin, G, Pradier, C, Tiger, F, et al.Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med 1996 ;22:17–25.
75.Shapiro, NI, Howell, MD, Talmor, D, et al.Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524–8.
76.Trzeciak, S, Dellinger, RP, Chansky, ME, et al.Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 2007;33:970–7.
77.Aduen, J, Bernstein, WK, Khastgir, T, et al.The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA 1994;272:1678–85.
78.Shapiro, N, Howell, MD, Bates, DW, et al.The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 2006;48:583,90, 590.
79.Kumar, A, Haery, C, Paladugu, B, et al.The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006;193:251–8.
80.Miner, JR, Heegaard, W, Mapes, A, et al.Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001;21:387–92.
81.Houck, PM, Bratzler, DW, Nsa, W, et al.Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637–44.
82.Kumar, A, Roberts, D, Wood, KE, et al.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96.
83.Bochud, PY, Glauser, MP, Calandra, T. Antibiotics in sepsis. Intensive Care Med 2001;27(Suppl 1):S33–48.
84.Simon, D, Trenholme, G. Antibiotic selection for patients with septic shock. Crit Care Clin 2000;16:215–31.
85.Hughes, WT, Armstrong, D, Bodey, GP, et al.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 ;34:730–51.
86.Marshall, JC, Maier, RV, Jimenez, M, et al.Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S513–26.
87.Moss, RL, Musemeche, CA, Kosloske, AM. Necrotizing fasciitis in children: Prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996;31:1142–6.
88.Feistritzer, C, Wiedermann, CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007;7:855–70.
89.Baillie, JK. Activated protein C: Controversy and hope in the treatment of sepsis. Curr Opin Investig Drugs 2007;8:933–8.
90.Abraham, E, Laterre, PF, Garg, R, et al.Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 ;353:1332–41.
91.Bernard, GR, Margolis, BD, Shanies, HM, et al.Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206–16.
92.Yildiz, O, Doganay, M, Aygen, B, et al.Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002;6:251–9.
93.Briegel, J, Forst, H, Haller, M, et al.Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723–32.
94.Bollaert, PE, Charpentier, C, Levy, B, et al.Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645–50.
95.Keh, D, Boehnke, T, Weber-Cartens, S, et al.Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003 02/15;167(4):512–20.
96.Minneci, PC, Deans, KJ, Banks, SM, et al.Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47–56.
97.Annane, D, Bellissant, E, Bollaert, PE, et al.Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004;329:480.
98.Annane, D, Sebille, V, Troche, G, et al.A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038–45.
99.Sprung, CL, Annane, D, Keh, D, et al.Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111–24.
100.Marik, PE, Zaloga, GP. Adrenal insufficiency during septic shock. Crit Care Med 2003;31:141–5.
101.Bourne, RS, Webber, SJ, Hutchinson, SP. Adrenal axis testing and corticosteroid replacement therapy in septic shock patients-local and national perspectives. Anaesthesia 2003;58:591–6.
102.Bouachour, G, Tirot, P, Gouello, JP, et al.Adrenocortical function during septic shock. Intensive Care Med 1995;21:57–62.
103.Rothwell, PM, Udwadia, ZF, Lawler, PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582–3.
104.Goodman, S, Sprung, CL, Ziegler, D, et al.Cortisol changes among patients with septic shock and the relationship to ICU and hospital stay. Intensive Care Med 2005;31:1362–9.
105.Keh, D, Sprung, CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S527–33.
106.Hebert, PC, Wells, G, Blajchman, MA, et al.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. transfusion requirements in critical care investigators, canadian critical care trials group. N Engl J Med 1999;340:409–17.
107.Fan, E, Needham, DM, Stewart, TE. Ventilatory management of acute lung injury and acute respiratory distress syndrome. JAMA 2005;294:2889–96.
108.Kallet, RH. Evidence-based management of acute lung injury and acute respiratory distress syndrome. Respir Care 2004;49:793–809.
109.Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000;342:1301–8.
110.Kollef, MH, Schuster, DP. The acute respiratory distress syndrome. N Engl J Med 1995;332:27–37.
111.Bernard, GR, Artigas, A, Brigham, KL, et al.The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818–24.
112.Hickling, KG, Walsh, J, Henderson, S, et al.Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994;22:1568–78.
113.Amato, MB, Barbas, CS, Medeiros, DM, et al.Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338:347–54.
114.Stewart, TE, Meade, MO, Cook, DJ, et al.Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. pressure- and volume-limited ventilation strategy group. N Engl J Med 1998;338:355–61.
115.Bidani, A, Tzouanakis, AE, Cardenas, VJ Jr, et al.Permissive hy-percapnia in acute respiratory failure. JAMA 1994;272:957–62.
116.Stocker, R, Neff, T, Stein, S, et al.Prone positioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. Chest 1997;111:1008–17.
117.Jolliet, P, Bulpa, P, Chevrolet, JC. Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome. Crit Care Med 1998;26:1977–85.
118.Gattinoni, L, Tognoni, G, Pesenti, A, et al.Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345:568–73.
119.Papazian, L, Gainnier, M, Marin, V, et al.Comparison of prone positioning and high-frequency oscillatory ventilation in patients with acute respiratory distress syndrome. Crit Care Med 2005;33:2162–71.
120.Van den Berghe, G, Wilmer, A, Hermans, G, et al.Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–61.
121.Malhotra, A. Intensive insulin in intensive care. N Engl J Med 2006;354:516–8.